PharmaCyte Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023
December 15, 2023 at 05:26 pm EST
Share
PharmaCyte Biotech, Inc. reported earnings results for the second quarter and six months ended October 31, 2023. For the second quarter, the company reported net income was USD 2.79 million compared to net loss of USD 1.88 million a year ago. Basic loss per share from continuing operations was USD 0.26 compared to USD 0.09 a year ago.
For the six months, net loss was USD 0.393401 million compared to USD 3.43 million a year ago. Basic loss per share from continuing operations was USD 0.85 compared to USD 0.17 a year ago.
PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.
PHARMACYTE BIOTECH, INC. 
